The U.S. Omnipod guidance cut is a key negative, suggesting slowing adoption or competitive pressure; monitor Q3 U.S. trends for confirmation. The strong EPS beat and international momentum provide some offset, but the stock may face headwinds until management demonstrates U.S. stabilization.
Price Chart
Executive Summary
Insulet reported Q2 2026 revenue of $801.7M (+23.5% YoY) and adjusted EPS of $1.66, beating consensus estimates by 14.3%, but lowered FY 2026 U.S. Omnipod constant currency growth guidance from 20-22% to 17-19%, signaling a meaningful deceleration in the domestic business.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $801.7M vs $649.1M YoY, +23.5% as reported, +22.7% constant currency
- GAAP EPS $1.37 (diluted); adjusted EPS $1.66, beating consensus $1.45 by 14.3%
- U.S. Omnipod revenue $544.1M (+20.1% YoY); International Omnipod $251.8M (+35.5% YoY, +32.9% constant currency)
- FY 2026 U.S. Omnipod constant currency growth guidance cut to 17-19% from prior 20-22%
- Total Omnipod FY constant currency guidance trimmed to 21-23% from 22-24%
- Adjusted operating margin 19.3% (+140 bps YoY); adjusted EPS growth guidance raised to 30% from 25%
- Voluntary medical device correction costs of $21.9M in Q2 related to March and May 2026 actions
Financial Impact
EPS beat $0.21 vs consensus ($1.66 vs $1.45), but FY U.S. growth guidance cut by ~3 percentage points
Risk Factors
- U.S. Omnipod growth deceleration from type 2 diabetes scaling challenges
- Voluntary medical device corrections creating ongoing warranty and reputational costs
- Competitive pressure from Tandem Diabetes Care and Medtronic's automated insulin delivery systems
- Potential further downward revision if Q3 trends disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001145197-26-000167 |
| Document: podd-20260805.htm | 0001145197-26-000167 |
| Document: 0001145197-26-000167-index-headers.html | 0001145197-26-000167 |
| Document: 0001145197-26-000167-index.html | 0001145197-26-000167 |
| Document: 0001145197-26-000167.txt | 0001145197-26-000167 |
| 8-K Data (Synthetic) | 0001145197-26-000167 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $132.30 $148.14 | ▲ +11.97% | ▲ +12.57% | $131.69 (−0.46%) |
Aug 3, 2026 8w ago | Press Release | $169.70 $148.66 | ▲ +12.40% | ▲ +13.64% | $131.69 (+22.40%) |
Jul 30, 2026 9w ago | Press Release | $165.68 $143.41 | ▲ +13.44% | ▲ +17.41% | $131.69 (+20.52%) |
Jul 24, 2026 10w ago | Institutional Cluster | $163.26 $147.92 | ▲ +9.39% | ▲ +13.02% | $131.69 (+19.34%) |
Jul 13, 2026 11w ago | Press Release | $159.12 $144.70 | ▼ −9.06% | ▼ −11.55% | $131.69 (−17.24%) |
Jul 3, 2026 12w ago | Press Release | $159.77 $165.35 | ▼ −3.49% | ▼ −4.06% | $131.69 (+17.58%) |
May 28, 2026 18w ago | Court Ruling | $141.98 $153.82 | ▼ −8.34% | ▼ −11.03% | $131.69 (+7.25%) |
May 6, 2026 21w ago | 8-K | $150.52 $143.30 | ▼ −4.80% | ▼ −7.58% | $131.69 (−12.51%) |
Mar 4, 2026 30w ago | 8-K | $240.55 $204.04 | ▼ −15.18% | ▼ −11.39% | $131.69 (−45.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access